Inovio Pharmaceuticals has been granted a patent for nucleic acid molecules encoding a modified consensus mesothelin antigen. The patent covers methods for treating mesothelin-expressing tumors and preventing their development, along with vaccines and compositions containing the modified antigen. Additionally, a specific protein sequence is claimed. GlobalData’s report on Inovio Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Inovio Pharmaceuticals, Personalized cancer vaccines was a key innovation area identified from patents. Inovio Pharmaceuticals's grant share as of May 2024 was 35%. Grant share is based on the ratio of number of grants to total number of patents.
Modified consensus mesothelin antigen protein
A recently granted patent (Publication Number: US11986517B2) discloses a protein with specific amino acid sequences that have potential applications in various fields. The patent claims cover proteins with amino acid sequences either directly from SEQ ID NO: 2 or sequences that are at least 96% identical to it. These proteins contain specific amino acids at positions 303, 583, and 585 relative to SEQ ID NO: 2, which are alanine, threonine, and valine, respectively. The inclusion of these specific amino acids is crucial for the functionality and effectiveness of the proteins as outlined in the patent claims.
Furthermore, the patent also emphasizes the importance of a protein comprising the exact amino acid sequence set forth in SEQ ID NO: 2. This specific sequence is highlighted as a key aspect of the invention, indicating its significance in the development of novel protein-based products or therapies. By clearly defining the essential amino acid sequence required for the protein, the patent provides a foundation for further research and development in the field. Overall, the patent's claims focus on the unique amino acid compositions of the proteins, underscoring their potential value in various applications within the scientific and commercial sectors.
To know more about GlobalData’s detailed insights on Inovio Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
